These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 29314404)
1. Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice? Donoghue K Addiction; 2018 Feb; 113(2):238-239. PubMed ID: 29314404 [No Abstract] [Full Text] [Related]
2. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of alcoholism - an update on approved and off-label medications. Soyka M; Müller CA Expert Opin Pharmacother; 2017 Aug; 18(12):1187-1199. PubMed ID: 28658981 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis. Kotake K; Hosokawa T; Tanaka M; So R; Banno M; Kataoka Y; Shiroshita A; Hashimoto Y Addiction; 2024 May; 119(5):815-832. PubMed ID: 38173342 [TBL] [Abstract][Full Text] [Related]
6. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis. Soyka M; Friede M; Schnitker J Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589 [TBL] [Abstract][Full Text] [Related]
7. Recent Developments in Pharmacotherapy of Alcoholism. Soyka M; Lieb M Pharmacopsychiatry; 2015 Jul; 48(4-5):123-35. PubMed ID: 25761458 [TBL] [Abstract][Full Text] [Related]
8. Opioid Receptor Antagonists in the Treatment of Alcoholism. Serecigni JG Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. Bahji A; Bach P; Danilewitz M; Crockford D; Devoe DJ; El-Guebaly N; Saitz R J Addict Med; 2022 Nov-Dec 01; 16(6):630-638. PubMed ID: 35653782 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for alcohol dependence: status of current treatments. Franck J; Jayaram-Lindström N Curr Opin Neurobiol; 2013 Aug; 23(4):692-9. PubMed ID: 23810221 [TBL] [Abstract][Full Text] [Related]
11. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940 [TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Gual A; He Y; Torup L; van den Brink W; Mann K; Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264 [TBL] [Abstract][Full Text] [Related]
13. [Medical management of alcohol use disorders]. Paille F Rev Prat; 2019 Oct; 69(8):909-916. PubMed ID: 32237660 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jonas DE; Amick HR; Feltner C; Bobashev G; Thomas K; Wines R; Kim MM; Shanahan E; Gass CE; Rowe CJ; Garbutt JC JAMA; 2014 May; 311(18):1889-900. PubMed ID: 24825644 [TBL] [Abstract][Full Text] [Related]
15. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Mann K; Bladström A; Torup L; Gual A; van den Brink W Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314 [TBL] [Abstract][Full Text] [Related]
16. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485 [TBL] [Abstract][Full Text] [Related]
17. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. Rösner S; Leucht S; Lehert P; Soyka M J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529 [TBL] [Abstract][Full Text] [Related]
18. Selecting an appropriate alcohol pharmacotherapy: review of recent findings. Castrén S; Mäkelä N; Alho H Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369 [TBL] [Abstract][Full Text] [Related]
19. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529 [TBL] [Abstract][Full Text] [Related]
20. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence. Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]